GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Price-to-Owner-Earnings

Sino Biopharmaceutical (HKSE:01177) Price-to-Owner-Earnings : 34.00 (As of May. 14, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Price-to-Owner-Earnings?

As of today (2024-05-14), Sino Biopharmaceutical's share price is HK$3.06. Sino Biopharmaceutical's Owner Earnings per Share (TTM) ended in Dec. 2023 was HK$0.09. It's Price-to-Owner-Earnings for today is 34.00.


The historical rank and industry rank for Sino Biopharmaceutical's Price-to-Owner-Earnings or its related term are showing as below:

HKSE:01177' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.05   Med: 27.84   Max: 52.78
Current: 34.22

During the past 13 years, the highest Price-to-Owner-Earnings of Sino Biopharmaceutical was 52.78. The lowest was 4.05. And the median was 27.84.


HKSE:01177's Price-to-Owner-Earnings is ranked better than
51.19% of 168 companies
in the Biotechnology industry
Industry Median: 35.165 vs HKSE:01177: 34.22

As of today (2024-05-14), Sino Biopharmaceutical's share price is HK$3.06. Sino Biopharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.14. Therefore, Sino Biopharmaceutical's PE Ratio for today is 22.17.

As of today (2024-05-14), Sino Biopharmaceutical's share price is HK$3.06. Sino Biopharmaceutical's EPS without NRI for the trailing twelve months (TTM) ended in was HK$0.12. Therefore, Sino Biopharmaceutical's PE Ratio without NRI for today is 26.61.

During the past 13 years, Sino Biopharmaceutical's highest PE Ratio without NRI was 62.17. The lowest was 4.04. And the median was 29.95.


Sino Biopharmaceutical Price-to-Owner-Earnings Historical Data

The historical data trend for Sino Biopharmaceutical's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Price-to-Owner-Earnings Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.86 31.46 5.99 34.10 38.56

Sino Biopharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.99 - 34.10 - 38.56

Competitive Comparison of Sino Biopharmaceutical's Price-to-Owner-Earnings

For the Biotechnology subindustry, Sino Biopharmaceutical's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Price-to-Owner-Earnings falls into.



Sino Biopharmaceutical Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Sino Biopharmaceutical's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=3.06/0.09
=34.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical  (HKSE:01177) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Sino Biopharmaceutical Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical (HKSE:01177) Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (HKSE:01177) Headlines

No Headlines